A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAndrew H. Wei, Jan Davidson‐Moncada, Jichao Sun et al.|Blood|2019Cited by 15
Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) InitiativePinkal Desai, Aaron D. Goldberg, Jacqueline S. Garcia et al.|Blood|2023Cited by 3
Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By <i>TP53</i> and <i>IDH1/2</i> Mutation: Results from the AML Real World Evidence (ARC) InitiativeOfir Wolach, Aaron D. Goldberg, Jacqueline S. Garcia et al.|Blood|2022Cited by 2
Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.Ofir Wolach, Aaron D. Goldberg, Pinkal Desai et al.|Journal of Clinical Oncology|2025Cited by 0
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review studyJacqueline S. Garcia, Aaron D. Goldberg, P Desai et al.|Leukemia & lymphoma/Leukemia and lymphoma|2026Cited by 0